$123 million Series B financing for Flare Therapeutics

Cambridge, USA-based discoverer of precision medicines for cancer and other diseases Flare Therapeutics today announced an oversubscribed $123 million Series B financing.

“Our investor support is testament to the rapid progress our team has made since launch in advancing the only company focused on rationally designing transcription factor targeting therapies,” said Dr Amit Rakhit, president and chief executive of Flare Therapeutics, which was launched in 2021, adding: “This will be a pivotal year for Flare as we progress our first precision oncology program, FX-909, into the clinic, continue to expand our collection of druggable transcription factor targets, and build a pipeline of potentially first-in-class therapies against genetically validated transcription factor targets for cancer.”

Proceeds will support FX-909 development